Table 2.
Summarized results of the included studies.
| Study [Ref] (year) | Disease or medication class | Mean medication adherence rate ± standard deviation | Medication adherence rate threshold | Probability to reach the targeted clinical outcome with the medication adherence threshold (odds ratio [OR], hazard ratio [HR], and confidence interval [CI]) | Percentage of patients below medication adherence threshold |
|---|---|---|---|---|---|
| Govani et al., 2017 | Adalimumab | MPR 0.94 ± 0.13 | 0.86 | Hazard Ratio (HR): 0.75 (95% CI 0.67–0.83) for a flare | 24% |
| Certolizumab | MPR 0.87 ± 0.14 | 0.87 | HR: 0.59 (95% CI 0.46–0.76) for a flare | 24% | |
| Karve et al., 2009 | Schizophrenia | MPR 0.738 ± 0.310 | 0.76 | OR: 0.456 for disease related hospitalization | – |
| PDC 0.724 ± 0.295 | 0.76 | OR: 0.430 for disease related hospitalization | – | ||
| Diabetes | MPR 0.763 ± 0.279 | 0.85 | OR: 0.449 for disease related hospitalization | – | |
| PDC 0.751 ± 0.266 | 0.85 | OR: 0.434 for disease related hospitalization | – | ||
| Hypertension | MPR 0.712 ± 0.304 | 0.82 | OR: 0.712 for disease related hospitalization | – | |
| PDC 0.702 ± 0.293 | 0.82 | OR: 0.708 for disease related hospitalization | – | ||
| Hyperlipidemia | MPR 0.731 ± 0.295 | 0.81 | OR: 0.591 for disease related hospitalization | – | |
| PDC 0.722 ± 0.284 | 0.81 | OR: 0.581 for disease related hospitalization | – | ||
| Congestive heart failure | MPR 0.619 ± 0.304 | 0.58 | OR: 0.856 for disease related hospitalization | – | |
| PDC 0.612 ± 0.295 | 0.58 | OR: 0.855 for disease related hospitalization | – | ||
| Lo-Ciganic et al., 2015 | Diabetes type II | 0.65 ± 0.26 | 0.46–0.94 | HR: 0.48-0.69 for all cause hospitalization according the patient health and medication complexity | – |
| Oleen-Burkey et al., 2011 | Multiple sclerosis | – | 0.7 | OR: 0.547 (95% CI 0.362–0.826) for relapse | 49.23% |
| Watanabe et al., 2013 | Statins | – | 0.9 | OR: 12.90 (95% CI 9.60–17.35) for 25% reduction of non-HDL cholesterol | – |
| OR: 11.29 (95% CI 8.61–14.80) for 25% reduction of LDL cholesterol | – | ||||
| OR: 9.11 (95% CI 6.62–12.53) for 25% reduction of total cholesterol | – | ||||
| Wu et al., 2009 | Heart failure | Dose count: 0.887 ± 0.156 | 0.88 | HR: 2.2 for time to first event for the non-adherent group | 44% |
| Dose day: 0.808 ± 0.228 | 0.88 | HR: 3.2 for time to first event for the non-adherent group | 44% |